Sort   by:  
 Page size 
UnknownPhase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Not available
S-EPMC4874204 | biostudies-literature
ProteomicsHuma Multiple Myeloma Cell line, AMO1, treated with NCP26, LC-MSMS analysis
The human multiple myeloma cell line, AMO1, was treated with NCP26, an ATP-competitive EPRS inhibitor, and a total proteome-wide analysis was performed to determine the effect of NCP26 treatment on protein dynamics.
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD029453 | Pride
Lc-msms Huma Ncp26 Multiple myeloma Cell line Tmt-labeling Amo1 
UnknownLenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Not available
S-EPMC5652871 | biostudies-literature
TranscriptomicsExpression of genetic adaptability of cancer cells under treatment selection pressure in multiple myeloma patients
Series GSE25262 patients on expression side. [Exon study] 11 myeloma patients at diagnosis and relapse examined with Exon expression chip
ORGANISM(S): Homo sapiens 
2013-02-13 | E-GEOD-37414 | biostudies-arrayexpress
TranscriptomicsPrognostic significance of copy-number alterations in multiple myeloma
Purpose Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown. Methods We performed a genome-wide analysis of malignant plasma cells from 192 newly myeloma patients using high-density, single-nucleotide polymorphism (SNP) arrays to identify...
ORGANISM(S): Homo sapiens 
2009-08-19 | E-GEOD-12896 | biostudies-arrayexpress
TranscriptomicsGenetic adaptability of cancer cells under treatment selection pressure in multiple myeloma patients.
Purpose Despite advances and significant improvement in survival, multiple myeloma (MM) remains incurable and nearly all patients relapse after treatment. Previous studies have shown a complex spectrum of diverse genetic alterations in almost all patients, but evolution of genomic rearrangements th...
ORGANISM(S): Homo sapiens 
2013-02-13 | E-GEOD-25262 | biostudies-arrayexpress
TranscriptomicsMinor clone provides a reservoir for relapse in multiple myeloma
In this study we addressed subclonal evolutionary process after treatment and subsequent relapse in multiple myeloma (MM) in a cohort of 24 MM patients treated either with conventional chemotherapy or with the proteasome inhibitor, bortezomib. Because MM is a highly heterogeneous disease coupled wit...
ORGANISM(S): Homo sapiens 
2013-02-13 | E-GEOD-37469 | biostudies-arrayexpress
TranscriptomicsMicroarray analysis to identify the molecular mechanisms whereby pDCs confer growth and drug resistance in MM cells
Multiple Myeloma (MM) remains incurable despite novel therapies, suggesting the need for further identification of factors mediating tumorigenesis and drug resistance. We performed microarray analysis to identify the molecular mechanisms whereby pDCs confer growth and drug resistance in MM cells. Co...
ORGANISM(S): Homo sapiens 
2009-07-31 | E-GEOD-17407 | biostudies-arrayexpress
UnknownRevised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Not available
S-EPMC4846284 | biostudies-literature
UnknownRobust estimation of bacterial cell count from optical density.
Not available
S-EPMC7499192 | biostudies-literature
Sort   by:  
 Page size